Longeveron ELPIS II Trial Did Not Meet Primary Efficacy Endpoint
-SEC Filing
Stocks · News reference
Longeveron Announces Phase 2b ELPIS II Trial Of Laromestrocel In Hypoplastic Left Heart Syndrome Misses Primary Efficacy Endpoint; Initiates Cost-Optimization Measures To Maximize Shareholder Value
The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Longeveron Inc. (LGVN)
Filed: 2026-09-23 AccNo: 0001213900-26-102611 Size: 257 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Why Generac Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Generac shares jumped 34.8% after an up-to-$8B Amazon data-center generator deal; other premarket movers included big gainers and losers.
Longeveron (LGVN) Shares Slide 59% After Hours: Here's Why
Longeveron shares fell 59% after hours after its ELPIS II trial missed its primary endpoint.